Clinical Trials › NCT04548999

Active, Not RecruitingPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
769
Target enrollment
16
U.S. states
Dec 2020
Start date
Sep 2027
Expected completion
Interventions / Treatments
OcrelizumabAntihistamineMethylprednisolone
Conditions studied
Multiple Sclerosis
Where this trial is running (24 sites)
Texas3 sites
Dallas · San Antonio · Sherman
California2 sites
Irvine · Stanford
Colorado2 sites
Aurora · Fort Collins
Florida2 sites
Clearwater · Tampa
Massachusetts2 sites
Boston · Worcester
New York2 sites
Great Neck · New York
Tennessee2 sites
Cordova · Nashville
Alabama1 site
Homewood
Arizona1 site
Phoenix
Kentucky1 site
Nicholasville
Maryland1 site
Lutherville
Michigan1 site
Farmington Hills
Missouri1 site
St Louis
New Jersey1 site
Neptune City
Ohio1 site
Cleveland
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (20)
MS centers in Texas

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View Texas centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play